Form 4 for ALGS Aligos Therapeutics, Inc.
Accepted 2023-10-27 00:00:00 ET · period of report 2023-10-25 · accession 0001610717-23-000319 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-27 | 2023-10-25 | ALGS | BLATT LAWRENCE | CEO, Dir | A - Grant | $0.76 | +610.3K | 1.85M | +49% | +$463.8K |
| D | 2023-10-27 | 2023-10-25 | ALGS | BLATT LAWRENCE | CEO, Dir | A - Grant | $0.13 | +305.1K | 305.1K | New | +$39.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-25 | A | A | 610,277 | $0.76 | 1,847,575 | D | — | — | |
| 2 | Derivative | Warrants (Right to Buy) | 2023-10-25 | A | A | 305,138 | $0.13 | 305,138 | D | $0.76 · 2023-10-25 to 2030-10-25 | 305,138 Common Stock |